At present, liquid biopsy is widely applied in late-stage cancer therapy selection and non-invasive prenatal tests. By enhancing sample quality, PHASIFY™ increases the sensitivity of these tests while reducing costs.

Research efforts aimed at implementing liquid biopsy for early-stage cancer screening must overcome the challenge of detecting low-concentration tumor DNA fragments.

By concentrating and purifying DNA from blood samples, PHASIFY™ can improve the identification of low frequency cancer mutations.

In so doing, our technology may help to realize the promise of liquid biopsy for early-stage cancer screening.